EricLefkofsky is the founder of Tempus, a company that works round the clock to provide physicians with relevant and updated information on cancer treatment, therapies and advanced technology. Recently, Lefkofsky announced his interest in assisting the Chicago University of Medicine with fighting breast cancer. The announcement came in at a crucial time when the University of Chicago had a drawback due to limited data provided to the physicians.
The entry of Tempus in the field would aid in the provision of molecular and sequencing data for breast cancer analysis and treatment. The partnership would also help with personalizing breast cancer treatment in patients. Tempus stated that it would analyze all data from approximately 1,000 patients who have breast cancer. The research will assist in determining the right treatment for patients. With this research, it will be easy for physicians and researchers to explore patterns that can help in predicting the response of patients in treatment. The objective of the partnership is coming up with important data reports to help in providing treatment.
While giving a speech of appreciation, Dr. Olufunmilayo Olopade of the University of Chicago said that although breast cancer tops the list of the most aggressive cancers in the world, there is little accessible data for the millions of patients. Olufunmilayo also said that the limited information provided on breast cancer is not enough to provide definitive treatments. The limiting information also leads physicians to make decisions on treatment without highly specified genetic information. This information always helps in coming up with better-targeted treatment solutions. Dr. Olufunmilayo said that his team was elated to be in partnership with Tempus and Eric on Facebook.
Tempus employs technology for genomic sequencing. This is done to help physicians make wise and valid treatment decisions. The objective of Tempus is coming up with personalized treatment solutions for patients. The company was established in 2015. It is headquartered in Chicago and more information click here.
Eric Lefkofsky is an executive entrepreneur. He is the founder of Tempus Start-up. He has invested in businesses, and Groupon is one of them. Tempus is his current success story. The company uses technology to come up with patients’ personalized treatment.
More visit: https://twitter.com/lefkofsky
Mikhail Blagosklonny is a professor of Oncology at the Roswell Park Cancer Institute in New York and a scientist who researches on aging and cancer. He is a holder of a Master’s Degree from the First Pavlov State Medical University, St. Petersburg, in internal medicine and a Ph.D. in cardiology and experimental medicine.
In 2002, he was appointed an associate professor of medicine at New York Medical College, Valhalla, New York. After the appointment, he took the position of senior scientist at Ordway Research Institute in Albany, New York. He remained in the position till 2009 when he was chosen as the professor of oncology at Roswell Park Cancer Institute. Mikhail’s study areas of interest include targeted cancer therapies, which defend healthy cells from damage, as well as the underlying mechanism of aging and anti-aging drugs. Read more on Impact Journals.
Mikhail Blagosklonny’s Hypothesis on the Role of TOR
Mikhail Blagosklonny has come up with a theory on the possible role of TOR signaling in aging and cancer and proposed using rapamycin. Rapamycin is a popular cancer drug that acts as a possible treatment for life extension. Mikhail is seen as one of the most passionate promoters of rapamycin in longevity research.
Mikhail Blagosklonny’s Role at Roswell Park Cancer Institute
Mikhail Blagosklonny joined the Department of Cell Stress Biology at Roswell Park Cancer Institute as an Associate Member and Associate Professor of Oncology. His study program is focused on several aspects of drug resistance as well as the molecular biology of melanoma and several blood malignancies including:
- Clarification of molecular mechanisms underlying oncogene.
- The unearthing of novel prognostic markers of melanoma.
- Understanding the mechanisms through which oxidative stress promotes oncogene.
- Why melanoma cells Gain invasive phenotypes.
- The role of Kruppelr-like transcription factors in the regulation of therapeutic outcomes.
Dr. Blagosklonny’s laboratory is also enthusiastically trailing the development of a novel class of small molecule inhibitors of C-MYC. C-MYC is an oncogenic transcription factor that transcribes more genetic product of 80% of human cancers. His study is aided by the American Cancer Society and National Cancer Institute.
Mikhail is the Chief Editor of Oncotarget, Cell cycle, and Aging. Also, he is an associate editor of therapy and Cancer Biology and is on the editorial board of Cell Differentiation and Death.
View Mikhail’s profile on Loop